Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020

Euro Surveill. 2020 Jul;25(28):2001260. doi: 10.2807/1560-7917.ES.2020.25.28.2001260.

Abstract

Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.

Keywords: SARS-CoV-2; antibody response; convalescent plasma; high titre; neutralising antibodies; symptomatic infection.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Neutralizing / blood*
  • Antibodies, Neutralizing / therapeutic use
  • Antibody Specificity
  • Betacoronavirus / immunology*
  • Blood Donors / statistics & numerical data
  • COVID-19
  • COVID-19 Serotherapy
  • Coronavirus Infections / blood*
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy*
  • England
  • Humans
  • Immunization, Passive / statistics & numerical data
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / blood*
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2
  • Statistics, Nonparametric
  • Time Factors
  • Young Adult

Substances

  • Antibodies, Neutralizing